ZYMEZymeworks Inc.

Nasdaq zymeworks.com


$ 9.02 $ 0.11 (1.23 %)    

Wednesday, 22-May-2024 15:59:58 EDT
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 9.02
$ 8.97
$ 0.00 x 0
$ 9.28 x 161
$ 8.93 - $ 9.31
$ 6.02 - $ 13.14
469,071
na
568.23M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-zymeworks-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $10 price target.

 citigroup-maintains-buy-on-zymeworks-lowers-price-target-to-16

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and lowers the price target from $17 to $16.

 wells-fargo-maintains-overweight-on-zymeworks-lowers-price-target-to-12

Wells Fargo analyst Derek Archila maintains Zymeworks (NASDAQ:ZYME) with a Overweight and lowers the price target from $14 t...

 zymeworks-q1-2024-gaap-eps-042-misses-029-estimate-sales-10030m-miss-17431m-estimate

Zymeworks (NYSE:ZYME) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.29) by ...

 zymeworks-presents-new-data-from-multiple-preclinical-development-programs-at-2024-american-association-for-cancer-research-annual-meeting

Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional bi...

 wells-fargo-maintains-overweight-on-zymeworks-raises-price-target-to-14

Wells Fargo analyst Derek Archila maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $12 t...

 hc-wainwright--co-maintains-neutral-on-zymeworks-raises-price-target-to-10

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Neutral and raises the price target fr...

 zymeworks-q4-adj-eps-016-beats-043-estimate

Zymeworks (NASDAQ:ZYME) reported quarterly Adj losses of $(0.16) per share which beat the analyst consensus estimate of $(0.43)...

 earnings-scheduled-for-march-6-2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

 zymeworks-to-present-preclinical-data-on-antibody-drug-conjugate-and-multispecific-platforms-at-the-american-association-for-cancer-research-annual-meeting

Five abstracts accepted for poster presentation highlight company's differentiated antibody-drug conjugate and multispecifi...

 recap-zymeworks-q3-earnings
Recap: Zymeworks Q3 Earnings
11/07/2023 21:40:50

 zymeworks-q3-eps-041-beats-047-estimate

Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.47) by ...

 earnings-scheduled-for-november-7-2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION